Bupropion and Midostaurin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Midostaurin
Bupropion
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased CYP2B6-substrate exposure
Interaction Deep Dive
Concomitant use of midostaurin with sensitive CYP2B6 substrates may decrease the substrate exposure. When midostaurin was coadministered with bupropion (a sensitive CYP2B6 substrate) the exposure of bupropion decreased by 48% and its metabolite, hydroxybupropion by 65%. Dose adjustments of the CYP2B6 substrate may be needed when coadministered with midostaurin1.
Why it happens (mechanism)
Induction of CYP2B6-substrate metabolism by midostaurin
Literature reports
1 report — tap to read
a) Coadministration of multiple doses of midostaurin 50 mg twice daily at steady-state with a single dose of bupropion (a sensitive CYP2B6 substrate) decreased the AUC(infinity) of bupropion by 48% and its metabolite, hydroxybupropion by 65% 1.
Common questions
Can I take Bupropion and Midostaurin together?
Decreased CYP2B6-substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Bupropion and Midostaurin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Bupropion or Midostaurin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: RYDAPT(R) oral capsules, midostaurin oral capsules. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2021. DailyMed
Keep reading about Midostaurin
Keep reading about Bupropion
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist